In the publication of the July 2025 issue of Blood Cancer Discover, the editors included a brief Commentary to the article as follows:

Epigenetic Subtypes of Burkitt Lymphoma with Biological and Clinical Distinctions

As disease subtyping forms a framework for prognosis, refining the classification of disease subtypes paves the way for more precise treatments. Current classification of Burkitt lymphoma (BL) is based on clinical and genetic parameters. In this study, Thomas and colleagues describe the disease at the level of DNA methylation patterns, or epitypes. Using a well-annotated set of data from a large retrospective cohort, they show that samples grouped by the abundance of methylation marks are associated with distinct clinical outcomes. If validated in additional cohorts and integrated into the current clinical standards, the findings could offer increased precision of risk assessment for BL patients.